<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259606</url>
  </required_header>
  <id_info>
    <org_study_id>CCRA</org_study_id>
    <nct_id>NCT04259606</nct_id>
  </id_info>
  <brief_title>Effect of Cassia Cinnamon on Arterial Stiffness Parameters in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Cassia Cinnamon on Arterial Stiffness Parameters in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus is considered a serious public health problem that has been raising
      worldwide. In Mexico, it is an important cause of morbi - mortality and it´s characterized by
      hyperglycemia that promotes an increase of cardiovascular risk through the impairment of
      arterial stiffness and endothelial function, which, in a chronic manner promotes the
      development of micro and macrovascular complications.

      Many nutraceuticals have been currently implemented aimed to improve glycemic control, and
      reduce cardiovascular risk and it´s complications, which results in a better quality of life
      in patients with type 2 diabetes mellitus.

      Cassia cinnamon pulverized bark has demonstrated to have vasodilator effect independent of
      endothelial mechanisms, probably regulating calcium influx or release into or within the
      cell, the later demonstrated in mice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, placebo control group, double blind clinical trial. 30 patients (male or
      female) from 40 to 65 years old with type 2 diabetes mellitus, less than 1 year of diagnosis,
      taking Metformin 850 mg daily, referred to the Experimental and Clinical Therapeutic
      Institute will be included.

      All patients should give written informed consent prior to be enrolled. The protocol was
      previously approved by the local ethics committee (Experimental and Clinical Therapeutic
      Institute) of University of Guadalajara, registration number: CEI/489/2019. Patients with
      other medical conditions, taking additional drugs or with more than 1 year of evolution will
      be excluded.

      Procedure:

      The entire study consists of a total of 5 visits, the first one (day - 7) is the screening
      visit where written informed consent, clinical history, anthropometric measurements and blood
      samples will be performed.

      The second or initial visit (day 0) consists of review of laboratory results, hemodynamic
      studies (i.e brachial - ankle pulse wave velocity and index for arterial stiffness and flow
      mediated dilation on brachial artery for endothelial function with VP1000 and UNEX EF devices
      respectively), and after randomization, start of intervention (either cassia cinnamon or
      placebo).

      The third and fourth visits (day 30 and 60) consist of evaluation of treatment adherence,
      side effects, blood tests, treatment renewal and general recommendations.

      The fifth and last visit (day 90) is similar to day 0 plus evaluation of treatment adherence
      and side effects. This is the end of intervention period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, randomized, double blind, with control group. The study consists in two groups assigned to take either cassia cinnamon or placebo. Both groups will be taken Metformin as first line therapy for type 2 diabetes mellitus</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial - ankle pulse wave velocity</measure>
    <time_frame>90 days</time_frame>
    <description>Change in the pulse wave velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow mediated dilation</measure>
    <time_frame>90 days</time_frame>
    <description>Change in the capacity of dilation of the brachial artery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial - ankle index</measure>
    <time_frame>90 days</time_frame>
    <description>Change in the systolic and diastolic pressures of the brachial and tibial arteries, the index is the result of dividing the last between the first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>4 visits: days 1, 30, 60 and 90.</time_frame>
    <description>Millimeters of mercury. mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>4 visits: days 1, 30, 60 and 90.</time_frame>
    <description>Milligrams over deciliters. mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>4 visits: days 1, 30, 60 and 90.</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>4 visits: days 1, 30, 60 and 90.</time_frame>
    <description>Total cholesterol, triglycerides, high density lipoprotein, very high density lipoprotein, low density lipoprotein. All of them expressed in milligrams over deciliters. mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Arterial Stiffness</condition>
  <arm_group>
    <arm_group_label>Cassia Cinnamon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cassia cinnamon, capsule of 1 gram each, taken every 8 hours before meals for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcined Magnesia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo consists in calcined magnesia, capsule of 1 gram each, taken every 8 hours before meals for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cassia Cinnamon</intervention_name>
    <description>Reddish - brown to light brown, typical sweet and aromatic free flowing powder.</description>
    <arm_group_label>Cassia Cinnamon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcined magnesia</intervention_name>
    <description>White, odor, color and flavorless thin powder.</description>
    <arm_group_label>Calcined Magnesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to the beginning of enrollment

          -  Men and women 40 to 65 years old

          -  Diagnosis of type 2 diabetes mellitus according to the American Diabetes Association
             criteria

          -  Fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/L) at least 8 h of fasting

          -  Plasma glucose ≥ 200 mg/dl (11.1 mmol/L) 2 hours after oral glucose tolerance test

          -  HbA1c ≥ 6.5 % (48 mmol/mol)

          -  Plasma glucose ≥ 200 mg/dl (11.1 mmol/L) in a random glucose test with typical
             symptoms of hyperglucemia or hyperglycemic crisis.

        Exclusion Criteria:

          -  HbA1c &lt; 6.5 % or &gt; 10 % or fasting glucose plasma &gt; 250 mg/dl

          -  Total serum cholesterol ≥ 240 mg/dl

          -  Triglycerides ≥ 400 mg/dl

          -  History of allergy to any of the components used in the study

          -  Consumption of additional drugs with known effects on glucose and lipids metabolism
             and weight reduction

          -  History of cardiovascular disease, blood abnormalities and/or kidney, pancreatic or
             thyroid disease

          -  Childbearing and breastfeeding women

          -  History of smoking within 12 months prior to beginning of study

          -  History of drug abuse and alcoholism

          -  Pacemaker bearing or any other permanent bioelectronic device that could modify or
             interfere with electrical bioimpedance tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Ofelia Hernández González, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Pascoe González, PhD</last_name>
    <phone>3331370639</phone>
    <email>spg0371@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María G Ramos Zavala, PhD</last_name>
    <phone>3339523367</phone>
    <email>ramos.zavala.mg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Universitario de Ciencias de la Salud</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Pascoe González, PhD</last_name>
      <phone>3331370639</phone>
      <email>spg0371@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>María G Ramos Zavala, PhD</last_name>
      <phone>3339523367</phone>
      <email>ramos.zavala.mg@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://pubchem.ncbi.nlm.nih.gov</url>
    <description>Chemical properties of bark cinnamon derived Cinnamaldehyde</description>
  </link>
  <reference>
    <citation>American Diabetes Association. Standards of Medical Care in Diabetes-2019 Abridged for Primary Care Providers. Clin Diabetes. 2019 Jan;37(1):11-34. doi: 10.2337/cd18-0105.</citation>
    <PMID>30705493</PMID>
  </reference>
  <reference>
    <citation>Rosas Y, Calles J. Documento de posición de la Asociación Latinoamericana de Diabetes (ALAD). Consenso de prediabetes. 2009;17:146-158</citation>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24.</citation>
    <PMID>22922414</PMID>
  </reference>
  <reference>
    <citation>Arauz A, Ruíz-Franco A. Enfermedad Vascular Cerebral. Rev Fac Medicina UNAM.2012;55:11-21</citation>
  </reference>
  <reference>
    <citation>Ritz E. Nephropathy in type 2 diabetes. J Intern Med. 1999 Feb;245(2):111-26. Review.</citation>
    <PMID>10081514</PMID>
  </reference>
  <reference>
    <citation>Javed S, Alam U, Malik RA. Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions. Rev Diabet Stud. 2015 Spring-Summer;12(1-2):63-83. doi: 10.1900/RDS.2015.12.63. Epub 2015 Aug 10. Review.</citation>
    <PMID>26676662</PMID>
  </reference>
  <reference>
    <citation>Pedraza L. Neuropatías diabéticas, formas clínicas y diagnóstico. Rev Med Clin.2009;20:681-686</citation>
  </reference>
  <reference>
    <citation>Julio R, Galleguillos I. Diabetes y enfermedad vascular periférica. Rev Med Clin. 2009;20:687-697</citation>
  </reference>
  <reference>
    <citation>Cervantes R, Presno J. Fisiopatología de la diabetes y los mecanismos de muerte de las células β pancreáticas. Rev. Endocrinol. Nutr.2013;21:98-106</citation>
  </reference>
  <reference>
    <citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441.</citation>
    <PMID>25538310</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011 May;34 Suppl 2:S202-9. doi: 10.2337/dc11-s221. Review.</citation>
    <PMID>21525456</PMID>
  </reference>
  <reference>
    <citation>de Oliveira Alvim R, Santos PCJL, Musso MM, de Sá Cunha R, Krieger JE, Mill JG, Pereira AC. Impact of diabetes mellitus on arterial stiffness in a representative sample of an urban Brazilian population. Diabetol Metab Syndr. 2013 Aug 21;5(1):45. doi: 10.1186/1758-5996-5-45.</citation>
    <PMID>23965633</PMID>
  </reference>
  <reference>
    <citation>Jia G, Aroor AR, DeMarco VG, Martinez-Lemus LA, Meininger GA, Sowers JR. Vascular stiffness in insulin resistance and obesity. Front Physiol. 2015 Aug 14;6:231. doi: 10.3389/fphys.2015.00231. eCollection 2015. Review.</citation>
    <PMID>26321962</PMID>
  </reference>
  <reference>
    <citation>Yeboah K, Antwi DA, Gyan B. Arterial Stiffness in Nonhypertensive Type 2 Diabetes Patients in Ghana. Int J Endocrinol. 2016;2016:6107572. Epub 2016 Sep 28.</citation>
    <PMID>27774104</PMID>
  </reference>
  <reference>
    <citation>Li X, Deng YP, Yang M, Wu YW, Sun SX, Sun JZ. Low-Grade Inflammation and Increased Arterial Stiffness in Chinese Youth and Adolescents with Newly-Diagnosed Type 2 Diabetes Mellitus. J Clin Res Pediatr Endocrinol. 2015 Dec;7(4):268-73. doi: 10.4274/jcrpe.2187.</citation>
    <PMID>26777037</PMID>
  </reference>
  <reference>
    <citation>Morales S, García-Salcedo JA, Muñoz-Torres M. [Pentosidine: a new biomarker in diabetes mellitus complications]. Med Clin (Barc). 2011 Mar 19;136(7):298-302. doi: 10.1016/j.medcli.2009.12.001. Epub 2010 Mar 11. Review. Spanish.</citation>
    <PMID>20226481</PMID>
  </reference>
  <reference>
    <citation>Cardoso CR, Salles GF. Aortic Stiffness as a Surrogate Endpoint to Micro- and Macrovascular Complications in Patients with Type 2 Diabetes. Int J Mol Sci. 2016 Dec 6;17(12). pii: E2044. Review.</citation>
    <PMID>27929441</PMID>
  </reference>
  <reference>
    <citation>Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, Seta F. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension. 2013 Dec;62(6):1105-10. doi: 10.1161/HYPERTENSIONAHA.113.01744. Epub 2013 Sep 23.</citation>
    <PMID>24060894</PMID>
  </reference>
  <reference>
    <citation>Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, Heffernan KS, Lakatta EG, McEniery CM, Mitchell GF, Najjar SS, Nichols WW, Urbina EM, Weber T; American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015 Sep;66(3):698-722. doi: 10.1161/HYP.0000000000000033. Epub 2015 Jul 9.</citation>
    <PMID>26160955</PMID>
  </reference>
  <reference>
    <citation>Suárez C, Ruilope LM. [New guidelines from the World Health Organization and the International Society of Hypertension for the management of hypertension: toward common guidelines]. Rev Esp Cardiol. 1999 Jun;52(6):381-2. Spanish.</citation>
    <PMID>10373770</PMID>
  </reference>
  <reference>
    <citation>Medagama AB, Bandara R. The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? Nutr J. 2014 Oct 21;13:102. doi: 10.1186/1475-2891-13-102. Review.</citation>
    <PMID>25331834</PMID>
  </reference>
  <reference>
    <citation>Chang CT, Chang WL, Hsu JC, Shih Y, Chou ST. Chemical composition and tyrosinase inhibitory activity of Cinnamomum cassia essential oil. Bot Stud. 2013 Dec;54(1):10. doi: 10.1186/1999-3110-54-10. Epub 2013 Aug 21.</citation>
    <PMID>28510850</PMID>
  </reference>
  <reference>
    <citation>Rao PV, Gan SH. Cinnamon: a multifaceted medicinal plant. Evid Based Complement Alternat Med. 2014;2014:642942. doi: 10.1155/2014/642942. Epub 2014 Apr 10. Review.</citation>
    <PMID>24817901</PMID>
  </reference>
  <reference>
    <citation>Vangalapati M, Satya S, Prakash S, Avanigadda S. A review on pharmacological activities and clinical effects of Cinnamon species. J Pharm Biol Chem Sci. 2012;3(1):653-663</citation>
  </reference>
  <reference>
    <citation>Akilen R, Tsiami A, Devendra D, Robinson N. Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. Diabet Med. 2010 Oct;27(10):1159-67. doi: 10.1111/j.1464-5491.2010.03079.x.</citation>
    <PMID>20854384</PMID>
  </reference>
  <reference>
    <citation>Xue YL, Shi HX, Murad F, Bian K. Vasodilatory effects of cinnamaldehyde and its mechanism of action in the rat aorta. Vasc Health Risk Manag. 2011;7:273-80. doi: 10.2147/VHRM.S15429. Epub 2011 Apr 28.</citation>
    <PMID>21603596</PMID>
  </reference>
  <reference>
    <citation>Kang YH, Yang IJ, Morgan KG, Shin HM. Cinnamyl alcohol attenuates vasoconstriction by activation of K⁺ channels via NO-cGMP-protein kinase G pathway and inhibition of Rho-kinase. Exp Mol Med. 2012 Dec 31;44(12):749-55. doi: 10.3858/emm.2012.44.12.083.</citation>
    <PMID>23178275</PMID>
  </reference>
  <reference>
    <citation>Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003 Dec;26(12):3215-8.</citation>
    <PMID>14633804</PMID>
  </reference>
  <reference>
    <citation>Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. J Int Soc Sports Nutr. 2006 Dec 28;3:45-53. doi: 10.1186/1550-2783-3-2-45.</citation>
    <PMID>18500972</PMID>
  </reference>
  <reference>
    <citation>Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatr. 1989 Feb;26(2):115-21.</citation>
    <PMID>2753525</PMID>
  </reference>
  <reference>
    <citation>Zócalo Y, Bia D. Presión aórtica central y parámetros clínicos derivados de la onda del pulso: evaluación no invasiva en la práctica clínica. Rev Urug Cardiol. 2014;29:215-230</citation>
  </reference>
  <reference>
    <citation>Gómez Marcos MA, Recio Rodríguez JI, Rodríguez Sánchez E, Patino Alonso MC, Gómez Sánchez L, García ortiz L. [The increase in the speed of the pulse wave is not associated with elevated central blood pressure in hypertensive patients with kidney disease]. Nefrologia. 2010;30(5):578-83. doi: 10.3265/Nefrologia.pre2010.June.10383. Spanish.</citation>
    <PMID>20613849</PMID>
  </reference>
  <reference>
    <citation>Calabia Martínez, J. Medida de la Velocidad de Onda de Pulso mediante Ecografía Doppler: Concordancia con el Método Complior.2016</citation>
  </reference>
  <reference>
    <citation>Sáez J. Distensibilidad arterial: un parámetro más para valorar el riesgo cardiovascular. SEMERGEN. 2008;34(6):284-90</citation>
  </reference>
  <reference>
    <citation>Polo C, Del Castillo M. El índice cintura-cadera. Revisión. Madrid: Centro de Medicina Deportiva, Comunidad de Madrid</citation>
  </reference>
  <reference>
    <citation>Compendio de Leyes y Reglamentos. Agenda de Salud 2002. Tercera edición. México: Ediciones fiscals ISEF, 2002</citation>
  </reference>
  <reference>
    <citation>Rabkin SW, Chan SH, Sweeney C. Ankle-brachial index as an indicator of arterial stiffness in patients without peripheral artery disease. Angiology. 2012 Feb;63(2):150-4. doi: 10.1177/0003319711410307. Epub 2011 Jun 15.</citation>
    <PMID>21676966</PMID>
  </reference>
  <reference>
    <citation>Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. Erratum in: J Am Coll Cardiol 2002 Mar 20;39(6):1082.</citation>
    <PMID>11788217</PMID>
  </reference>
  <reference>
    <citation>Mozos I, Malainer C, Horbańczuk J, Gug C, Stoian D, Luca CT, Atanasov AG. Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases. Front Immunol. 2017 Aug 31;8:1058. doi: 10.3389/fimmu.2017.01058. eCollection 2017. Review.</citation>
    <PMID>28912780</PMID>
  </reference>
  <reference>
    <citation>Hamilton SJ, Watts GF. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud. 2013 Summer-Fall;10(2-3):133-56. doi: 10.1900/RDS.2013.10.133. Epub 2013 Aug 10. Review.</citation>
    <PMID>24380089</PMID>
  </reference>
  <reference>
    <citation>Bia D, Zócalo Y. Rigidez arterial: evaluación no invasiva en la práctica clínica. Rev Urug Cardiol. 2014;29:39-59</citation>
  </reference>
  <reference>
    <citation>Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010 Oct;31(19):2338-50. doi: 10.1093/eurheartj/ehq165. Epub 2010 Jun 7.</citation>
    <PMID>20530030</PMID>
  </reference>
  <reference>
    <citation>Christen A, Miranda A, Caride S, Armentano R, Ramírez A, Sánchez R. Velocidad de la onda de pulso: relevancia de la edad en normotensión, hipertensión escencial e hipertensión limítrofe. Rev. Argent. Cardiol. 2015;83:112-118</citation>
  </reference>
  <reference>
    <citation>Sánchez-Martínez M, Cruz J, Graciani A, García E, Artalejo F, Banegas J. Velocidad de la onda de pulso y presión arterial central: valores normales y de referencia en personas mayores en España. Rev Esp Cardiol. 2018:1-3</citation>
  </reference>
  <reference>
    <citation>Zhu R, Liu H, Liu C, Wang L, Ma R, Chen B, Li L, Niu J, Fu M, Zhang D, Gao S. Cinnamaldehyde in diabetes: A review of pharmacology, pharmacokinetics and safety. Pharmacol Res. 2017 Aug;122:78-89. doi: 10.1016/j.phrs.2017.05.019. Epub 2017 May 27. Review.</citation>
    <PMID>28559210</PMID>
  </reference>
  <reference>
    <citation>Hajimonfarednejad M, Ostovar M, Raee MJ, Hashempur MH, Mayer JG, Heydari M. Cinnamon: A systematic review of adverse events. Clin Nutr. 2019 Apr;38(2):594-602. doi: 10.1016/j.clnu.2018.03.013. Epub 2018 Apr 5.</citation>
    <PMID>29661513</PMID>
  </reference>
  <reference>
    <citation>Diabetes, O. M. S. Informe Mundial sobre la Diabetes. Ginebra. 2016</citation>
  </reference>
  <reference>
    <citation>Instituto Nacional de Estadística y Geografía. Principales causas de mortalidad por residencia habitual, grupos de edad y sexo del fallecido. 2016</citation>
  </reference>
  <reference>
    <citation>International Diabetes Federation. IDF Diabetes Atlas. 8ª edición. 2017</citation>
  </reference>
  <reference>
    <citation>Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, Gómez-Humarán IM, Gaona-Pineda EB, Gómez-Acosta LM, Rivera-Dommarco JÁ, Hernández-Ávila M. [Methodological design of the National Health and Nutrition Survey 2016]. Salud Publica Mex. 2017 May-Jun;59(3):299-305. doi: 10.21149/8593. Spanish.</citation>
    <PMID>28902317</PMID>
  </reference>
  <reference>
    <citation>National Institute for Healt and Care Excellence. Type 2 diabetes: prevention in people at high risk. Pub. Health Guidel. 2012</citation>
  </reference>
  <reference>
    <citation>Prevención secundaria, diagnóstico, tratamiento y vigilancia de la enfermedad cerebral isquémica. México Secretaría de Salud. 2008</citation>
  </reference>
  <reference>
    <citation>Martínez-Murillo C, Aguilar-Arteaga ML, Velasco-Ortega E, Alonso-González R, Castellanos-Sinco H, Romo-Jiménez A, Vargas-Ruiz A, Torres-Arreola L, Viniegra-Osorio A. [Clinical guideline for diagnosis and treatment of the thromboembolic venous disease]. Rev Med Inst Mex Seguro Soc. 2011 Jul-Aug;49(4):437-49. Review. Spanish.</citation>
    <PMID>21982196</PMID>
  </reference>
  <reference>
    <citation>Millán-Gámez YK, Wacher-Rodarte NH, Bravo-Ortiz JC, Garrido-Gaspar NH, Mendoza-Topete R, Martínez-Ruiz AM, Miller-Arrevillaga G, Ramírez-Nájera A. [Clinical practice guidelines. Diagnosis and treatment of diabetic retinopathy]. Rev Med Inst Mex Seguro Soc. 2011 Sep-Oct;49(5):551-62. Spanish.</citation>
    <PMID>22185860</PMID>
  </reference>
  <reference>
    <citation>Harrison´s Principles of Internal Medicine (2015). Kasper D, Hauser S, Jameson J. McGrawHill</citation>
  </reference>
  <reference>
    <citation>Herbs &amp; natural supplements an evidence-based guide. 2010. Braun L, Cohen M. ELSEVIER</citation>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Sara Pascoe Gonzalez</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Cassia cinnamon</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Pulse wave velocity</keyword>
  <keyword>Brachial - ankle index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

